Study study type PathologyT1T0Patientssample sizesROB Results

metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)

versus pegylated liposomal doxorubicin
avelumab alone
JAVELIN ovarian 200 (A vs doxorubicin), 2021
  NCT02580058
RCTmetastatic/advanced OC (mOC) - 2nd line (L2)avelumabPegylated liposomal doxorubicinPatients with platinum-resistant/refractory epithelial ovarian, fallopian tube, or peritoneal cancer, unselected for PD-L1 expression (ovarian cancer) a maximum of three previous lines for platinum-sensitive disease (most recent line containing platinum) with no previous systemic therapy for platinum-resistant disease188 / 190some concern
inconclusive
  • inconclusive 14 % increase in deaths (OS) (PE)
  • statistically significant 68 % increase in progression or deaths (PFS) (PE)
avelumab plus pegylated liposomal doxorubicin
JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021
  NCT02580058
RCTmetastatic/advanced OC (mOC) - 2nd line (L2)avelumab plus PLDPegylated liposomal doxorubicinPatients with platinum-resistant/refractory epithelial ovarian, fallopian tube, or peritoneal cancer, unselected for PD-L1 expression (ovarian cancer) a maximum of three previous lines for platinum-sensitive disease (most recent line containing platinum) with no previous systemic therapy for platinum-resistant disease188 / 190some concern
inconclusive
  • inconclusive 11 % decrease in deaths (OS) (PE)
  • inconclusive 22 % decrease in progression or deaths (PFS) (PE)